case_images: PMC11785621_01
case_images: Histopathological features of the tumor located in the second lumbar vertebrae. a Hematoxylin-eosin staining (HE) (x 400). b Hepatocyte marker is positive in cytoplasm (x 200). c Glypican3 marker is negative in cytoplasm (x 200). d Arginase1 marker is positive in the cytoplasm (x 200)
case_images: 12328_2024_2044_Fig1_HTML.jpg
case_images: PMC11785621_01_12328_2024_2044_Fig1_HTML.jpg
case_images: Fig1
case_images: The results of CT-guided aspiration cytology showed Class V, and immunostaining showed Hepatocyte-positive, Glypican-3-negative, Arginase1-positive, and S100-negative histology, leading to the diagnosis of HCC (Fig. 1).
case_images: Contrast-enhanced computed tomography (CT) imaging test and Fluorine-18-fluorodeoxyglucose positron emission tomography (FGD-PET) imaging test results before and after treatment. a-d Before RT and durvalumab plus tremelimumab. e-h 9 months after RT and durvalumab plus tremelimumab, 8 courses of durvalumab
case_images: 12328_2024_2044_Fig2_HTML.jpg
case_images: PMC11785621_01_12328_2024_2044_Fig2_HTML.jpg
case_images: Fig2
case_images: After completion of radiotherapy, his symptoms improved, and his AFP, AFP-L3, and DCP levels were confirmed to have decreased (Fig. 2).
case_images: Clinical course and trend in tumor markers of the patient. After radiotherapy (39 Gy/13fr) and durvalumab plus tremelimumab administration were started, tumor markers (AFP and DCP) decreased and remained low for a long time
case_images: 12328_2024_2044_Fig3_HTML.jpg
case_images: PMC11785621_01_12328_2024_2044_Fig3_HTML.jpg
case_images: Fig3
case_images: Contrast CT and PET-CT showed that the lumbar spine tumor had shrunk, SUVmax was 3.3 (Fig. 3), the accumulation was reduced, and the mRECIST CR was maintained for a long period of time.